NCT01757717View on ClinicalTrials.gov

Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis

NACompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Metastatic or Recurrent Lesions in the SpineMetastatic or Recurrent Lesions in the Pelvis
Interventions
RADIATION

Ir-192 high dose rate (HDR)

Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01757717 - Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis | Biotech Hunter | Biotech Hunter